Skip to main content
SpringerLink
Log in

Advanced and controlled drug delivery systems in clinical disease management

  • Review
  • Published:
Pharmacy World and Science Aims and scope Submit manuscript

Abstract

Advanced and controlled drug delivery systems are important for clinical disease management. In this review the most important new systems which have reached clinical application are highlighted.

Microbiologically controlled drug delivery is important for gastrointestinal diseases like ulcerative colitis and distally localized Crohn's disease. In cardiology the more classic controlled release systems have improved patient compliance and decreased side effects. In the treatment of intractable pain the spinal and transdermal route is well documented.

In neurology the flattened peak-through levels of antiepileptic drugs and anti Parkinson's drugs represents a more predictable kinetic profile.

Tracheal delivery of corticosteroids and sympaticomimetics in asthma and Chronic Obstructive Pulmonary Disease is fully accepted in clinical practice: delivery by this route results in better efficacy and a better safety profile.

In gynaecology the delivery of pulsatile hormones (LHRH) is used for pregnancy induction, while transdermal oestrogens are promising in the prevention of osteoporosis.

In surgical practice the use of antibiotic impregnated bone cement and antibiotic impregnated biodegradable collagens is well established.

To prevent infections intravascular catheters coated with heparin or antibiotics are used.

In ophthalmology the Ocusert® systems provide a controlled release of different drugs in the eye.

Most spectacular is the clinical introduction of the first liposomal drugs: amfotericine B and daunorubicine. Liposomal formulations of these drugs have enhanced activity and decreased toxicity compared to conventional formulations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Montague MJ. Biotechnology CE Series: Biotechnology and the future of medicine. Pharm Pract News 1993 (jan.); p3:p13:p31.

  2. DavisSS. Delivery for biopharmaceuticals. J Pharm Pharmacol 1992: 44 (suppl. 1):186–90.

    Google Scholar 

  3. MorrowJD. The oral cephalosporins: a review. Am J Med Sci 1992;303:35–9.

    Google Scholar 

  4. BeglingerC, DreweJ, KisselT. The absorption site of cyclosporin in human gastro-intestinal tract. Br J Clin Pharmacol 1993; 33: 39–43.

    Google Scholar 

  5. TrullAK, TanKK, TanL, AlexanderGJ, JamiesonNV. Absorption of cyclosporin from conventional and new microemulsion oral formulations in liver transplant recipients with external biliary diversion. Brit J Clin Pharmacol 1995;39:627–31.

    Google Scholar 

  6. PardridgeWM. Preface: overview of brain drug delivery. Adv Drug Deliv Rev 1995; 15: 1–3.

    Google Scholar 

  7. DelhaasEM, BrouwersJRBJ. Intrathecal baclofen overdose: report of 7 events in 5 patients and review of literature. Int J Clin Pharmacol Ther Tox 1991; 29: 274–80.

    Google Scholar 

  8. AlbrightAL, BarronWB, FasickMP, PolinkoP, JanoskyJ. Continuous intratecal baclofen infusion for spasticity of cerebral origin. JAMA 1993; 270: 2475–7.

    Google Scholar 

  9. BrouwersJRBJ, CramerK, GulyasJ, Van derKamHJ, SijtsmaJ. Intraportal 5-FU for colorectal hepatic metastasis and adjuvant treatment: a tolerance dose study in: “Progress in Clinical Pharmacy” editors NFMuller & YAHekster. Eur Soc Clin Pharm, Amsterdam Medical Press, Noordwijkerhout 1990; 340–42.

    Google Scholar 

  10. Swiss Group for Clinical Cancer Research (SAKK). Long-term results of single course of adjuvant intraportal chemotherapy for colorectal cancer. Lancet 1995; 345: 349–53.

    Google Scholar 

  11. KoksCHW, BrouwersJRBJ, SleijfferDTh. Regional infusion of fluoropyrimidines for hepatic metastasis of colorectal cancer. Pharm Weekbl [Sci] 1988; 10: 69–75.

    Google Scholar 

  12. KemenyN, SeiterK, ContiJA, CohenA, BertinoJR, SigurdsonER, et al. Hepatic arterial floxuridine and leucovorin for unresectable liver metastasis for colorectal carcinoma. Cancer 1994; 73; 1134–42.

    Google Scholar 

  13. Braat DDM. Multiple pregnancies in pulsatile GnRH treatment. Thesis Free University of Amsterdam, Amsterdam 1992.

  14. RubinsteinA. Microbially controlled drug delivery to the colon. Biopharm Drug Disp 1990; 11: 465–75.

    Google Scholar 

  15. BjarnasonI, McPhersonAJ. Delivery, safety and efficacy of 5-aminosalicylate preparations. Inflammopharmacol 1993; 3: 277–87.

    Google Scholar 

  16. JarnerotG. New salicylates as maintenance treatment in ulcerative colitis. Gut 1994; 35: 1155–8.

    Google Scholar 

  17. ChristensenLA, FallingborgJ, JacobsenBA, AbildgaardK, RasmussenHH, HansenSH, et al. Comparative bioavailability of 5-aminosalicylic acid from a controlled-release preparation and azo-bound preparation. Alim Pharmacol Ther 1994; 8: 289–94.

    Google Scholar 

  18. MethaRP. Nephropathy from 5-aminosalicylate preparations. Inflammopharmacol 1993; 2: 297–300.

    Google Scholar 

  19. ThuluvathPJ, NincovicM, CalamJ, AndersonM. Mesalazine induced interstitial nephritis. Gut 1994; 35: 1493–6.

    Google Scholar 

  20. LöfbergR. New steroids for inflammatory bowel disease. Inflam Bowel Dis 1995; 1: 135–41.

    Google Scholar 

  21. MulderCJJ, TytgatGNJ. Review article: topical corticosteroids in inilammatory bowel disease. Alim Pharmacol Therap 1993; 7: 125–30.

    Google Scholar 

  22. MellerDDM, MolemaG. Targeting of drug to the liver. Sem Liver Dis 1995; 15:202–56.

    Google Scholar 

  23. HillemanDE, BanakarUV. Issue in contemporary drug delivery, Part VI: Advanced cardiac drug formulations. J Pharm Techn 1992; 8: 203–11.

    Google Scholar 

  24. WhiteWB, AndersRJ, McIntyreJM, BlackHR, SicaDA and the Verapamil Study Group. Nocturnal dosing of a novel delivery system of verapamil for systemic hypertension. Am J Cardiol 1995; 76: 375–80.

    Google Scholar 

  25. BadlerM, HadadS, GolombG, BarelS, SamaraE, SalachOA, et al. Pharmacokinetic analysis of two new sustained release products of dilthiazem designed for twice and once daily treatment. Biopharm Drug Disp 1994; 15: 45–52.

    Google Scholar 

  26. MeredithPA, ElliottHL. FDA guidelines on through:peak ratios in the evaluation of antihypertensive agents. United States Food and Drug Administration. J Cardiovasc Pharmacol 1994; 23 (Suppl 5) S26–30.

    Google Scholar 

  27. BrouwersJRBJ. Orale toedienings vormen met gereguleerde afgiften. Stichting Anselmus, Heesch, The Netherlands 1989; 49–58.

    Google Scholar 

  28. HagenN, FlynneP, HagsH, Mac DonaldN. Guidelines for managing chronic non-malignant pain: opioid and other agents. Can Family Physician 1995; 41: 49–53.

    Google Scholar 

  29. DelhaasEM, BrouwersJRBJ. The spinal and epidural administration of narcotic analgesics in cancer patients. Royal Soc Med 1989 Congres Series nr 149: 91–3.

    Google Scholar 

  30. LeCorreP, PolardE, ChevannetF, LeVergeR. Morphine-controlled release from microspheres for site-specific delivery (abstract 456). Brit J Anesth 1995; 74 (Suppl 1): 139.

    Google Scholar 

  31. OralU, IsikG, OzbekH, GülerI. Intranasal fentanyl administration for postoperative pain (Abstract 458). Intranasal alfentaryl administration for postoperative pain (A459). Brit J Anaesth 1995; 75 (Suppl 1): 139.

    Google Scholar 

  32. WongPK, AsburgAJ, WardKM, DonellD, WrayH, StamponeP et al. Fentanyl by metered dose breath-actuated inhaler as analgesic after total abdominal hysterectomy. A clinical evaluation (Abstract 460). Brit J Anes 1995; 74: 140.

    Google Scholar 

  33. MaloneyCM, KesnerRK, KlemG, BockenstetteJ. The rectal administration of MS-Contin: clinical implications for use in end-stage cancer. Am J Hospice Palliative Care 1989; 6: 34–5.

    Google Scholar 

  34. MoolenaarF, FietsG, VisserJ, MejjerDKF. Prelimary study on the absorption profile after rectal and oral administration of methadone in human volunteers. Pharm Weekbl [Sci] 1984; 6: 237–40.

    Google Scholar 

  35. HammingCD, VickersAP, SmithG, GrahamNB, McNeilME. The morphine hydrogel suppository: a new sustained-release rectal preparation. Brit J Anesth 1988; 61: 221–7.

    Google Scholar 

  36. ConnoF, RipamontiC, SaitiL, MacEachernT, HansonJ, BrueraE. Role of rectal route in treating cancer pain: a randomized cross-over clinical trail of oral versus rectal morphine administration in opioid-naive cancer patients with pain. J Clin Oncol 1995; 13: 1004–8.

    Google Scholar 

  37. SchulzmanSA. Oral transmucosal fentanyl citrate for premedication of children undergoining laceration repair. Ann Emerg Med 1984; 24:1059–64.

    Google Scholar 

  38. GerwelsJW. Oral transmucosal fentanyl citrate premedication in patients undergoining outpatient dermatologic procedures. J Dermatol Surg Oncol 1994; 201:823–26.

    Google Scholar 

  39. DuncanL, WildsmithJAW. Liposomal local anaesthetics (Editorial). Brit J Anaesth 1995; 75: 260–1.

    Google Scholar 

  40. VavraI, PaulusHE. Controlled-release and enteric-coated formulations of NSAIDs. In. therapeutic applications of NSAIDs: subpopulations and new formulations. Editor: J.P.Famaey & H.E.Paulus. Marcel Dekker Inc. New York 1992; p. 373–83.

    Google Scholar 

  41. HollanderD. Gastro-intestinal complications of NSAIDs: prophylactic and therapeutic strategies. Am J Med 1994; 96: 274–81.

    Google Scholar 

  42. JanknegtR, BrouwersJRBJ, VanRielPLCM. Drug evaluation for non steroidal anti-inflammatory drugs by the SOJA method (Dutch). Ziekenhuisfarmacie (Neth.) 1995; 11: 94–106.

    Google Scholar 

  43. Anonymous. Drugs for Parkinson's disease reviewed. Drug Ther Bull 1995; 33: 49–52.

  44. DavisJM, MetalonL, WanatabeMD, BlakeL. Depot antipsychotic drugs place in therapy. Drugs 1994; 47:741–773.

    Google Scholar 

  45. WHO. Mechanism of action, safety and efficacy of intrauterine devices. WHO Tech Rep Ser no. 753, 1987.

  46. NaessenT, PerssonI, ThorL, MallminH, LjunghallS, Berstrom. Maintained bone density at advanced ages after longterm treatment with low dose oestradiol implants. Brit J Obstet Gynaecol 1993; 100:454–9.

    Google Scholar 

  47. SandersonPJ. Leading Article: Preventing infections orthopaedic implants. J Antimicrob Chemoth 1989; 24: 277–80.

    Google Scholar 

  48. DiMaioFr, HalloranJJ, QualeJM. In vitro elution of ciprofloxacin from polymethylmethacrylate beads. Orth Res 1994; 12: 79–82.

    Google Scholar 

  49. BrienPW, SalvataEA, KleinR, BrauseB, SternS. Antibiotic impregnated bone cement in total hip arthroplasty. An in vivo comparison of the elution properties of tobramycin and vancomycin. Clin Orthop 1993; 296: 242–8.

    Google Scholar 

  50. GerhartTN, RouxPD, HanffPA, HorowitzGL, RenshawAA, HayesWC. Antibiotic loaded biodegradable bone cement for prophylaxis and treatment of experimental osteomylitis. Orthop Res 1993; 11: 250–5.

    Google Scholar 

  51. JörgensenLG. Clinical and pharmacokinetic evaluation of gentamicin containing collagen in groin wound infections. Eur J Vasc Surg 1991; 5: 87–91.

    Google Scholar 

  52. HasselbachvonC. Klinik und Pharmakokinetiek von Kollagen-Gentamicin als adjuvante Lokal therapie knöcherner Infektion. Unfallchirung 1989; 93: 459–70.

    Google Scholar 

  53. BandijkDF, EssesGE. Prosthetic graft infection. Surg Clin Nort Am 1994; 74: 571–90.

    Google Scholar 

  54. BergaminiTM, McCurryTM, BernardJD, HoegKL, CorpusRA, PeytonJC, et al. Antibiotic efficacy against staphylococcus epidermidis adherent to vascular grafts. Vasc Forum 1994; 2: 92–3.

    Google Scholar 

  55. Goëau-BrissonnièreO, MercierF, NicolasMH, BacourtF, CoggiaM, LebrautC, et al. Treatment of vascular graft infection by in situ replacement with a rifampicin-bonded gelatin-sealed Dacron graft. J Vasc Surg 1994; 19: 739–44.

    Google Scholar 

  56. GoldmannDA, PieGB. Pathogenesis of infections related to intravascular catheterisation. Clin Microbiol Rev 1993; 6: 176–92.

    Google Scholar 

  57. AppelgrenP, RansjöU, BindslevL, LarmO. Does surface heparinisation reduce bacterial colonisation of central venous catheters? Lancet 1995; 345: 130 (letter).

    Google Scholar 

  58. TebbsSE, ElliotTSJ. Modification onf central venous catheter polymers to prevent in vitro microbial colonisation. Eur J Clin Microbiol Infect Dis 1994; 13: 111–7.

    Google Scholar 

  59. RaadI, DarouicheR, HachenR, SacilowskiM, BodeyGP. Antibiotics and prevention of microbial colonisation of catheters. Antimicrob Agents Chemother 1995; 39: 2397–2400.

    Google Scholar 

  60. SaettoneMF, SalminenL. Ocular inserts for topical delivery. Adv Drug Deliv Rev 1995; 16: 95–106.

    Google Scholar 

  61. ZimmerA, KreuterJ. Microspheres and nanoparticles used in ocular delivery systems. Advanced Drug Deliv Rev 1995; 16: 61–73.

    Google Scholar 

  62. MeisnerD, MezeiM. Liposome ocular delivery systems. Advanced Drug Deliv Rev 1995; 16: 75–93.

    Google Scholar 

  63. ErnestJT. Intraocular device for cytomegalovirus infection. Lancet 1995; 346: 983–4.

    Google Scholar 

  64. BergersJJ, tenHagenTLM, vanEttenEWM, Bakker-WoudenbergIAJM. Liposomes as delivery systems in the prevention and treatment of infectious diseases. PWS 1995; 17: 1–11.

    Google Scholar 

  65. DeMarieS, JanknegtR, Bakker-WoudenbergIAJM. Clinical use of liposomal and lipid-complexed amphotericin B. J Antimicrob Chemother 1994; 33: 907–16.

    Google Scholar 

  66. TollenaarJ, RingdenO. Lipid formulation of amphotericin B less toxicity but at what economic cost? Drug Safety 1995; 13: 207–18.

    Google Scholar 

  67. GraysonLS, HansbroughJF, Zapata-SirventR, RoehrbornAJ, KimT, KimS. Soft tissue infection prophylaxis with gentamicin encapsulated in multi-vascular liposomes: results from a prospective, randomized trial. Crit Care Med 1995; 23: 84–91.

    Google Scholar 

  68. OmarRF, DussereN, DésormeauxA, PoulesL, TremblayM, BeauchampD, et al. Liposomal encapsulation of foscarnet protects against hypocalcemia induced by free foscarnet. Antimicrob Agents Chemother 1995; 39: 1973–8.

    Google Scholar 

  69. KimS. Liposomes as carriers of cancer chemotherapy: current status and future prospects. Drugs 1993; 46: 618–38.

    Google Scholar 

  70. GillPS, EspinaBM, MuggiaF, CabrialisS, TulpuleA, EsplinJA et al. Phase I/II clinical and phartmacokinetic evaluation of liposomal daunorubicin. J. Clin Oncol 1995; 13:996–1003.

    Google Scholar 

  71. PresantCA, ScolaroM, KennedyP, BlayneyDW, FlanagenB, LisakJ, et al. Liposomal daunorubicin treatment of HIV associated Kaposi's sarcoma. Lancet 1993; 341: 1242–43.

    Google Scholar 

  72. BremH, PlantadosiS, BurgerPC, WalkerM, SelkerR, VickNA, et al. Placebo-controlled trial of safety and efficacy of intra operative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet 1995; 345: 1008–12.

    Google Scholar 

  73. SiegallCB. Targeted toxins as anticancer agents. Cancer 1994; 74: 1006–12.

    Google Scholar 

  74. KennedyFP. Recent developments in insulin delivery techniques: current status and future potential. Drugs 1991; 42: 213–27.

    Google Scholar 

  75. PetersAM. The utility of99mTc-HMPAO-leukocytes for imaging infection. Sem Nucl Med 1994; 24: 110–27.

    Google Scholar 

  76. DatzFL. Indium-111-labeled leukocytes for the detection of infection: current status. Sem Nucl Med 1994; 24: 92–109.

    Google Scholar 

  77. RubinRH, FischmanA. The use of radiolabeled nonspecific immunoglobulin in the detection of focal inflammation. Sem Nucl Med 1994; 24: 169–79.

    Google Scholar 

  78. FischmanAJ, BabichJW, RubinRH. Infection imaging with technetium-99m-labeled chemotactic peptide analogs. Sem Nucl Med 1994; 24: 154–168.

    Google Scholar 

  79. SahaGB, MclntyreWJ, GoRT. Radiopharmaceuticals for brain imaging. Sem Nucl Med 1994; 24: 324–49.

    Google Scholar 

  80. HawkinsRE, LewelynMB, RusselSJ. Adapting antibodies for clinical use. Brit Med J 1993; 305: 1348–52.

    Google Scholar 

  81. BuckleyNA, DawsonAH, ReithDA. Controlled-release of drugs in overdose. Drug Saf 1994; 12: 73–84.

    Google Scholar 

  82. Anonymous. Controlled release formulations delay and prolong linical effects following overdose. Drugs Ther Persp 1995; 5 (7): 11–13.

  83. DavisSS. Delivery systems for biopharmaceuticals. J Pharm Pharmacol 1992; 44 (Suppl 1): 186–90.

    Google Scholar 

  84. ChalfinDB, HolbeinMEB, FeinAM, CarlonGC. Cost-effectiveness of monoclonal antibodies to Gram-negative endotoxin in the treatment of Gram-negative sepsis in ICU patients. JAMA 1993; 269: 249–54.

    Google Scholar 

  85. WherryJC, PenningtonJE, WenzelRP. Tumor necrosis factor and the therapeutic potential of anti-tumor necrosis factor antibodies. Crit Care Med 1993; 241: S 436–440.

    Google Scholar 

  86. HurleyJC. Reappraisal of the role of endotoxin in the sepsis syndrome. Lancet 1993; 341: 1133–5.

    Google Scholar 

  87. DeitchEA. Cytokines yes, cytokines no, cytokinesmay be. Crit Care Med 1993; 21: 817–19.

    Google Scholar 

  88. BlauHM, SpringerML. Gene therapy a novel form of drug delivery. New Engl J Med 1995; 333: 1204–7.

    Google Scholar 

  89. GlennieJL, WoloschukDMM, HallKW. High technology drugs for cancer: the decision process for adding to a formulary. Pharmaco Economics 1993; 4: 405–13.

    Google Scholar 

  90. RhoderJ, ThomasG. Nicotine treatment in ulcerative colitis: current status. Drugs 1995; 49: 157–60.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Groningen-Utrecht Institute for Drug Exploration (GUIDE), Division of Pharmacokinetics and Clinical Pharmacy, Department of Social Pharmacy and Pharmacoepidemiology, State University Groningen, Antonius Deusinglaan 2, 9713 AW, Groningen, The Netherlands

    J. R. B. J. Brouwers (Professor of Clinical and Hospital Pharmacy)

Authors
  1. J. R. B. J. Brouwers
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brouwers, J.R.B.J. Advanced and controlled drug delivery systems in clinical disease management. Pharm World Sci 18, 153–162 (1996). https://doi.org/10.1007/BF00820726

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00820726

Keywords

Search

Navigation